A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer

Objectives The objective of this study was to assess and compare the sentinel lymph node (SLN) detection rate with indocyanine green (ICG) and near-infrared fluorescence imaging versus blue dye using the robotic platform in patients with uterine cancer. Methods We identified all patients with uterine cancer undergoing SLN mapping using ICG or blue dye on the robotic platform from January 2011 to December 2013. Our institutional SLN algorithm and pathologic processing protocol were adhered to uniformly. We compared detection rates of SLNs stratified by dye used. Appropriate statistical tests were used. Results A total of 472 patients were identified. ICG was used in 312 patients (66%) and blue dye in 160 patients (34%). Successful mapping was achieved in 425 (90%) of 472 patients. Mapping was bilateral in 352 patients (75%) and unilateral in 73 patients (15%); 47 patients (10%) did not map. Successful mapping was achieved in 295 (95%) of 312 patients using ICG compared with 130 (81%) of 160 patients using blue dye (P < 0.001). Mapping was bilateral in 266 (85%) of 312 patients in the ICG group compared with 86 (54%) of 160 in the blue dye group (P < 0.001). Additional lymph node dissection beyond removal of the SLNs was performed in 122 patients (39%) mapped with ICG compared with 98 patients (61%) mapped with blue dye (P < 0.001). Conclusions The SLN detection rate was superior when mapping with ICG rather than blue dye. Bilateral mapping was significantly improved, resulting in a lower rate of additional lymphadenectomy.

[1]  A. Ferenczy,et al.  Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. , 2015, Gynecologic oncology.

[2]  J. Sehouli,et al.  Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer , 2015, Archives of Gynecology and Obstetrics.

[3]  D. Levine,et al.  Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery , 2015, Annals of Surgical Oncology.

[4]  A. Weaver,et al.  Multicenter study assessing the detection of stage IIIC endometrial cancer in intermediate- and high-risk tumors between a contemporary sentinel node mapping versus historical comprehensive lymphadenectomy approach , 2015 .

[5]  A. Fader,et al.  A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. , 2014, Gynecologic oncology.

[6]  Douglas A Levine,et al.  Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. , 2014, Gynecologic oncology.

[7]  N. Abu-Rustum Update on sentinel node mapping in uterine cancer: 10‐year experience at Memorial Sloan–Kettering Cancer Center , 2014, The journal of obstetrics and gynaecology research.

[8]  R. Barakat,et al.  Pathologic Ultrastaging Improves Micrometastasis Detection in Sentinel Lymph Nodes During Endometrial Cancer Staging , 2013, International Journal of Gynecologic Cancer.

[9]  L. Haas,et al.  Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. , 2012, Gynecologic oncology.

[10]  R. Barakat,et al.  The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. , 2012, Gynecologic oncology.

[11]  R. Rouzier,et al.  Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). , 2011, The Lancet. Oncology.

[12]  D. Levine,et al.  Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? , 2009, Gynecologic oncology.

[13]  R. Barakat,et al.  The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. , 2009, Gynecologic oncology.

[14]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[15]  M. Parmar,et al.  Lymphadenectomy in endometrial cancer – Authors' reply , 2009, The Lancet.

[16]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[17]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .